See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
Population pharmacokinetics of ensitrelvir in healthy participants and participants with SARS-CoV-2 infection in the SCORPIO-SR study
Population pharmacokinetics of ensitrelvir in healthy participants and participants with SARS-CoV-2 infection in the SCORPIO-SR study
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19
Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19